Nationwide Fund Advisors increased its position in shares of Novavax Inc. (NASDAQ:NVAX) by 1.1% during the second quarter, Holdings Channel reports. The institutional investor owned 243,288 shares of the biopharmaceutical company’s stock after buying an additional 2,626 shares during the period. Nationwide Fund Advisors owned 0.09% of Novavax worth $1,769,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in NVAX. Moors & Cabot Inc. bought a new stake in shares of Novavax during the second quarter worth $119,000. BlackRock Inc. raised its stake in shares of Novavax by 138.7% in the first quarter. BlackRock Inc. now owns 19,870 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 11,547 shares in the last quarter. Mariner Investment Group LLC bought a new stake in shares of Novavax during the second quarter worth $154,000. Commerzbank Aktiengesellschaft FI raised its stake in shares of Novavax by 38.8% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 22,917 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 6,410 shares in the last quarter. Finally, Parametrica Management Ltd raised its stake in shares of Novavax by 43.1% in the second quarter. Parametrica Management Ltd now owns 29,760 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 8,960 shares in the last quarter. Institutional investors and hedge funds own 79.84% of the company’s stock.
Shares of Novavax Inc. (NASDAQ:NVAX) traded down 4.29% during mid-day trading on Friday, hitting $1.56. 9,370,024 shares of the stock traded hands. The firm has a 50 day moving average of $4.12 and a 200 day moving average of $5.77. The company’s market cap is $422.50 million. Novavax Inc. has a 12 month low of $1.16 and a 12 month high of $9.23.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $8.03 million. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The firm’s quarterly revenue was down 82.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.08) EPS. Equities analysts anticipate that Novavax Inc. will post ($1.09) EPS for the current fiscal year.
A number of brokerages have weighed in on NVAX. Chardan Capital decreased their target price on shares of Novavax from $5.75 to $1.50 and set a “neutral” rating for the company in a research note on Tuesday, September 20th. Vetr upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 target price for the company in a research note on Wednesday, July 13th. Piper Jaffray Cos. downgraded shares of Novavax from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $14.00 to $1.00 in a research report on Friday, September 16th. Wedbush downgraded shares of Novavax from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $14.00 to $2.00 in a research report on Friday, September 16th. Finally, Ladenburg Thalmann downgraded shares of Novavax from a “buy” rating to a “neutral” rating in a research report on Friday, September 16th. Seven research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Novavax currently has an average rating of “Hold” and an average target price of $7.06.
In other Novavax news, Director Gail Boudreaux purchased 100,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The shares were purchased at an average cost of $1.45 per share, for a total transaction of $145,000.00. Following the completion of the transaction, the director now owns 200,000 shares of the company’s stock, valued at approximately $290,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John Trizzino purchased 46,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The shares were acquired at an average price of $2.17 per share, for a total transaction of $99,820.00. Following the completion of the transaction, the senior vice president now directly owns 85,564 shares of the company’s stock, valued at approximately $185,673.88. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by insiders.
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax Inc. (NASDAQ:NVAX).
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.